Natera Inc, which sells non-invasive prenatal disease screening tests, on Wednesday said it has priced its initial public offering of 10 million common shares at $18.00 each, which is at the top end of its estimated range of $17 to $18 apiece.
In addition, Natera has granted the underwriters a 30-day option to purchase up to an additional 1.5 million to cover over-allotments, if any.
The shares are expected to begin trading on the Nasdaq Global Select Market on July 2 under the symbol “NTRA.” The offering is expected to close on July 8.
The company had previously filed to offer 6 million shares at a range of $15 to $17 each.
Natera, which was founded in 2003, recorded sales of $179 million for the 12 months ended March 2015.
by RTT Staff Writer
For comments and feedback: [email protected]